We are live on ! Find out more
SBFM icon

Sunshine Biopharma

1 hedge funds and large institutions have $262K invested in Sunshine Biopharma in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1 → 1 (0)

0.8% less ownership

Funds ownership: 2.6% → 1.8% (-0.8%)

100% less capital inflows, than outflows

Capital inflows: $0 | Capital outflows: $53K

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

SBFM Hedge Fund Activity: Q4 2022 in Review

1 of the 6,245 institutional investors tracked by Wall St. Rank reported a position in Sunshine Biopharma (SBFM) for Q4 2022, worth a combined $262K — down 23% from $341K a quarter earlier.

Fund positioning in SBFM was balanced in Q4 2022: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

The largest seller was Two Sigma Investments, cutting an estimated $29K.

  • 1 institutional investor held Sunshine Biopharma (SBFM) as of Q4 2022, unchanged from Q3 2022.
  • Funds reported $262K of Sunshine Biopharma stock for Q4 2022, down 23% quarter-over-quarter.
  • 0 funds opened new Sunshine Biopharma positions in Q4 2022 and 0 closed out.
  • The largest Sunshine Biopharma seller in Q4 2022 was Two Sigma Investments, an estimated $29K sold.

Based on aggregated 13F filings for Q4 2022.